Your browser doesn't support javascript.
loading
Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
Marras, Connie; Fereshtehnejad, Seyed-Mohammad; Berg, Daniela; Bohnen, Nicolaas I; Dujardin, Kathy; Erro, Roberto; Espay, Alberto J; Halliday, Glenda; Van Hilten, Jacobus J; Hu, Michele T; Jeon, Beomseok; Klein, Christine; Leentjens, Albert F G; Mollenhauer, Brit; Postuma, Ronald B; Rodríguez-Violante, Mayela; Simuni, Tanya; Weintraub, Daniel; Lawton, Michael; Mestre, Tiago A.
Afiliación
  • Marras C; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
  • Fereshtehnejad SM; Division of Neurology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
  • Berg D; Department of Neurology, Christian-Albrechts-University, Kiel, Germany.
  • Bohnen NI; Departments of Radiology & Neurology, University of Michigan, University of Michigan Udall Center, Ann Arbor, Michigan, USA.
  • Dujardin K; Center of Excellence for Parkinson's Disease, CHU Lille, Univ Lille, Inserm, Lille Neuroscience & Cognition, Lille, France.
  • Erro R; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, Baronissi, Italy.
  • Espay AJ; James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
  • Halliday G; Brain and Mind Centre and Faculty of Medicine and Health School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
  • Van Hilten JJ; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Hu MT; Nuffield Department of Clinical Neurosciences, Oxford University and John Radcliffe Hospital, West Wing, Neurology Department, Level 3, Oxford, United Kingdom.
  • Jeon B; Department of Neurology, Seoul National University Hospital, Seoul, South Korea.
  • Klein C; Institute of Neurogenetics, University of Luebeck, Luebeck, Germany.
  • Leentjens AFG; Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Mollenhauer B; Paracelsus-Elena-Klinik, Kassel, Department of Neurology, University Medical Center Goettingen, Kassel, Germany.
  • Postuma RB; Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
  • Rodríguez-Violante M; National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Simuni T; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Weintraub D; Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania; Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
  • Lawton M; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Mestre TA; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Mov Disord ; 39(3): 462-471, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38243775
ABSTRACT
The International Parkinson and Movement Disorder Society (MDS) created a task force (TF) to provide a critical overview of the Parkinson's disease (PD) subtyping field and develop a guidance on future research in PD subtypes. Based on a literature review, we previously concluded that PD subtyping requires an ultimate alignment with principles of precision medicine, and consequently novel approaches were needed to describe heterogeneity at the individual patient level. In this manuscript, we present a novel purpose-driven framework for subtype research as a guidance to clinicians and researchers when proposing to develop, evaluate, or use PD subtypes. Using a formal consensus methodology, we determined that the key purposes of PD subtyping are (1) to predict disease progression, for both the development of therapies (use in clinical trials) and prognosis counseling, (2) to predict response to treatments, and (3) to identify therapeutic targets for disease modification. For each purpose, we describe the desired product and the research required for its development. Given the current state of knowledge and data resources, we see purpose-driven subtyping as a pragmatic and necessary step on the way to precision medicine. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Guideline Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Guideline Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article